Radiopharm (RADX) Theranostics announced the signing of a supply agreement with Cyclotek to radiolabel RAD 402 with Terbium-161 in Australia, which supports the initiation of a Phase 1 clinical trial. RAD 402 is an anti-Kallikrein Related Peptidase 3 monoclonal antibody radiotherapeutic labelled with the radionuclide 161Tb for treatment of prostate cancer. “This agreement is an important milestone for the development of RAD 402 and is the last step needed to submit for ethics approval and begin our Phase 1 clinical trial in prostate cancer,” said Riccardo Canevari, CEO and Managing Director of Radiopharm Theranostics. “We are very appreciative of the entire team at Cyclotek for their support as we work together to bring an innovative new treatment option to patients battling prostate cancer.”
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RADX:
- Radiopharm Theranostics Limited – American Depositary Shares trading resumes
- Radiopharm granted U.S. FDA FTD for RAD101
- Radiopharm announces dosing of first patient in Phase 1 HEAT trial
- Radiopharm reports preclinical Lu177-B7H3-mAb data
- Radiopharm pipeline ‘dramatically’ undervalued, says JonesResearch